StrikePoint Gold completes acquisition of Northumberland gold project from Newmont subsidiaries
Bitget2026/10/08 11:31StrikePoint Gold closed its acquisition of Newmont subsidiaries’ Northumberland Gold Project in Nevada’s Walker Lane. Trading resumed following closing, reflecting a share consolidation announced on Sept. 29, 2026. Northumberland carries an independent July 31, 2026 MRE of 2.86 million oz AuEq indicated, 1.57 million oz AuEq inferred. Working capital totals about C$90 million post-closing, positioning the company to advance drilling within about a month. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Strikepoint Gold Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610080730NEWSFILECNPR____20261008_318008_1) on October 08, 2026, and is solely responsible for the information contained therein.
- StrikePoint Gold closed its acquisition of Newmont subsidiaries’ Northumberland Gold Project in Nevada’s Walker Lane.
- Trading resumed following closing, reflecting a share consolidation announced on Sept. 29, 2026.
- Northumberland carries an independent July 31, 2026 MRE of 2.86 million oz AuEq indicated, 1.57 million oz AuEq inferred.
- Working capital totals about C$90 million post-closing, positioning the company to advance drilling within about a month.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
